ANCA Vasculitis: Why It Is Mistaken for Other Diseases, How Rituximab Changed Treatment, and What Remission Means for Patients

Research-informed explainer — last updated April 12, 2026

ANCA-associated vasculitis is a rare autoimmune condition that attacks small blood vessels in the kidneys, lungs, sinuses, and other organs — and because its symptoms look like many more common diseases, the average diagnosis is delayed by 6–12 months, during which organ damage accumulates. The 2010 RAVE trial established rituximab as equivalent to cyclophosphamide for induction of remission, fundamentally changing a treatment strategy that had been unchanged for decades.

This article draws on research by Carol Langford, MD, at the Cleveland Clinic, the key author on the RAVE rituximab vs. cyclophosphamide trial (2,686 citations), the RITUXVAS confirmatory trial (721 citations), and the NEJM trial of mepolizumab for eosinophilic granulomatosis with polyangiitis (1,010 citations); Eli Miloslavsky, MD, at Massachusetts General Hospital, who published on clinical outcomes of ANCA treatment by antibody type (258 citations), management of ANCA vasculitis in BMJ (96 citations), and rituximab for relapses (74 citations); Jason Knight, MD, Professor at the University of Michigan, whose work on peptidylarginine deiminase (PAD4) inhibition and vascular damage (436 citations) provides the mechanistic context for why B-cell depletion with rituximab is particularly rational in ANCA disease; Kenneth Warrington, MD, Chair of Rheumatology at Mayo Clinic, who provides the differential diagnosis framing from large-vessel vasculitis; and Leonard Calabrese, DO, R.J. Fasenmeyer Chair of Clinical Immunology at the Cleveland Clinic, who developed the disease-specific activity index for Wegener's granulomatosis (464 citations) used to measure treatment response.

The three types of ANCA vasculitis

ANCA-associated vasculitis (AAV) encompasses three related conditions, all defined by inflammation of small blood vessels and the presence of ANCA antibodies:

• Granulomatosis with polyangiitis (GPA), formerly called Wegener's: granulomatous inflammation of the upper and lower respiratory tract and kidneys; most common in white adults aged 40–65
• Microscopic polyangiitis (MPA): predominantly kidney and lung involvement without granulomas; more strongly associated with MPO-ANCA
• Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss: distinguished by severe asthma, eosinophilia, and sinusitis before vasculitis develops

Why diagnosis is so often delayed

The presentations that lead patients to other specialists first include:

• Chronic sinusitis or ear disease that does not respond to antibiotics (ENT)
• Hearing loss or nasal septal perforation (ENT, allergist)
• Blood in the urine on routine urinalysis (primary care or nephrology)
• Cough, shortness of breath, or hemoptysis (pulmonology)
• Rash or skin nodules (dermatology)
• Peripheral neuropathy (neurology)

Any of these in combination — particularly upper respiratory symptoms plus kidney abnormalities — should prompt ANCA testing. Dr. Calabrese's Wegener's vasculitis activity index (464 citations) systematizes the organ-based assessment that allows tracking of where disease is active.

The ANCA antibodies: PR3 vs. MPO

Two ANCA antibody types define clinical risk profiles:

• PR3-ANCA (c-ANCA pattern): strongly associated with GPA; higher relapse rate after achieving remission
• MPO-ANCA (p-ANCA pattern): associated with MPA and some GPA; lower relapse rate; higher risk of chronic kidney disease

Dr. Miloslavsky's outcomes analysis (258 citations) showed that PR3-ANCA patients had significantly higher rates of relapse and required more aggressive maintenance therapy. This antibody type now informs both induction choice and the duration of maintenance therapy.

How rituximab changed treatment

Before 2010, cyclophosphamide was the only proven induction agent — effective but carrying significant risks including bladder cancer, infertility, and infection. The RAVE trial (2,686 citations), co-authored by Dr. Langford, randomized 197 patients with severe AAV to rituximab 375 mg/m² weekly for four doses versus daily oral cyclophosphamide for three to six months. Rituximab was non-inferior to cyclophosphamide for complete remission at 6 months (64% vs. 53%, p<0.001 for non-inferiority) and was superior in patients with relapsing disease (67% vs. 42% remission). Both groups received the same glucocorticoid taper.

The 2013 RITUXVAS trial (721 citations) confirmed these findings in a broader European cohort. Rituximab is now guideline-recommended as first-line induction for most patients with severe GPA or MPA, and is preferred for young patients concerned about fertility, those with relapsing disease, and those in whom cyclophosphamide is contraindicated.

For EGPA, mepolizumab (an anti-IL-5 monoclonal antibody) was studied in the NEJM trial (1,010 citations) co-authored by Dr. Langford — 300 mg subcutaneously monthly significantly reduced relapse rates and allowed steroid tapering, receiving FDA approval for EGPA in 2017.

Induction, then maintenance

Remission induction (rituximab or cyclophosphamide plus glucocorticoids) is followed by maintenance therapy. Options include:

• Rituximab 500 mg every 6 months (most commonly used)
• Azathioprine or methotrexate for lower-risk maintenance

Dr. Langford's earlier work (183 citations) demonstrated that using methotrexate for maintenance after cyclophosphamide induction achieved acceptable relapse rates, establishing the induction-maintenance concept that rituximab regimens now follow.

Dr. Miloslavsky's rituximab-for-relapses study (74 citations) showed sustained responses to rituximab re-dosing at relapse, supporting a strategy of rituximab maintenance or rituximab at relapse for PR3-positive patients.

What remission means and why relapse is common

Remission in AAV means no clinical evidence of active vasculitis — no active urine sediment, no respiratory symptoms attributable to vasculitis, stable or improving kidney function. However, remission is not cure. Relapse rates are 20–50% over 5 years, significantly higher in PR3-ANCA-positive GPA patients. Patients require ongoing ANCA monitoring, urinalysis, and creatinine checks even when feeling well. Maintenance therapy is typically continued for at least 18–24 months, with the duration driven by antibody type and relapse history.

Questions to ask your doctor

• Which ANCA antibody am I positive for — PR3 or MPO — and how does that affect my relapse risk?
• Is rituximab or cyclophosphamide the better choice for me given my age, fertility concerns, and disease severity?
• What maintenance therapy will follow induction, and for how long?
• How will I be monitored for relapse after achieving remission?
• Does my disease involve my kidneys, and if so, will a kidney biopsy be needed?
• If I have EGPA, should I be evaluated for mepolizumab?

The bottom line

ANCA-associated vasculitis is a serious but treatable condition where early diagnosis and the right induction therapy — now typically rituximab — prevent irreversible organ damage. Remission is achievable in the majority of patients, but long-term surveillance for relapse is essential because relapse rates remain substantial, especially in PR3-ANCA-positive disease. Treatment decisions should be made with a rheumatologist experienced in systemic vasculitis.